Streptococcus mutans sigX -inducing Peptide Inhibits Candida albicans Virulence and Oral Candidiasis through the Ras1-cAMP-Efg1 Pathway

Kaiwen Zhang,Ivy Guofang Sun,Binyou Liao,Yichun Yang,Huangshui Ma,Aiming Jiang,Song Chen,Qiang Guo,Biao Ren
DOI: https://doi.org/10.1016/j.ijantimicag.2023.106855
IF: 15.441
2023-05-21
International Journal of Antimicrobial Agents
Abstract:Oral candidiasis is the most common fungal infectious disease in human oral cavity and Candida albicans is the major pathogenic agent. The rising drug resistance and the lack of new types of antifungals greatly increase the challenges for treating fungal infections. Targeting hyphal transition provides a promising strategy to inhibit C. albicans virulence and overcome drug resistance. This study aimed to investigate the effects and mechanisms of sigX -inducing peptide (XIP), a quorum-sensing signal peptide secreted by Streptococcus mutans , on C. albicans hyphal development and biofilm formation in vitro and oropharyngeal candidiasis in vivo . XIP significantly inhibited C. albicans yeast-to-hypha transition and biofilm formation in a dose dependent manner arranged from 0.01 to 0.1 μM. XIP significantly downregulated expression of genes from the Ras1-cAMP-Efg1 pathway ( RAS1, CYR1, TPK2, EFG1 , and UME6 ), a key pathway to regulate C. albicans hyphal development. Importantly, XIP reduced the levels of key molecules cAMP and ATP from this pathway, while the addition of exogenous cAMP and overexpression of RAS1 restored the hyphal development inhibited by XIP. XIP also lost its hyphal inhibitory effects on ras1 Δ/Δ and efg1 Δ/Δ strains. These results furtherly confirmed that XIP inhibited the hyphal development through downregulating the Ras1-cAMP-Efg1 pathway. To evaluate the therapeutic effects of XIP on oral candidiasis, a murine oropharyngeal candidiasis model was employed. XIP effectively reduced the infected epithelial area, fungal burden, hyphal invasion, and inflammatory infiltrates. Our results revealed the antifungal effects of XIP and highlighted that XIP can be a potential antifungal peptide against C. albicans infection.
pharmacology & pharmacy,infectious diseases,microbiology
What problem does this paper attempt to address?